Drug developer Generate Biomedicines raises $400 million in US IPO

(February 26, 2026) by Reuters

Founded by Flagship in 2018, Generate Biomedicines uses AI-driven technology to move beyond traditional trial-and-error drug discovery and develop new protein-based therapies, with its pipeline centered on immunology and oncology.

Generate’s lead drug candidate for severe asthma, GB-0895, is currently in a late-stage trial, with full enrollment in the study expected by the first half of 2028.